GEN-MKT-18-7897-A
Mar 22, 2023 | Blogs, Discovery, Echo® MS+ system, Pharma | 0 comments
Read time: 1 min
Have you thought about introducing new technology into your high-throughput drug discovery lab? Here are 5 reasons the Echo® MS system could make a difference for you.
1. Increased sample throughput While a traditional fast LC-MS/MS run can take nearly 10 hours per plate, a 384-well plate of samples can take approximately 10 minutes per plate with the Echo® MS system. This means that study data can be available on the day samples are prepared and with the reliability of MS/MS.
2. Reduced carryover Moving away from LC-MS/MS eliminates the challenge of potential carryover. Acoustic Droplet Ejection technology removes the need for physical contact between the autosampler needle and the sample.
3. Method sensitivity Detection levels in the low nanomolar range are typically required in a high-throughput drug discovery lab and are readily achieved by the Echo® MS system.
4. Sample preparation savings Simply prepare the samples in an appropriate solvent and load them into a qualified microplate. Only 2.5 nL of precious sample is required for each analysis.
5. Data accuracy The Echo® MS system uses the trusted SCIEX Triple Quad 6500+ mass spectrometer to provide excellent Z’ values with MS/MS reliability.
Learn more about how the Echo® MS system can support high-throughput drug discovery in these technical notes Development of an acetylcholinesterase biochemical assay using the SCIEX Echo® MS system, Accelerating synthetic biology with very fast screening of metabolites in fermentation broth (sciex.com) might be of interest. Or visit sciex.com.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network